Combination of Tapentadol Nasal Spray and Radiotherapy for Managing Moderate-to-Severe Pain from Lytic Bone Metastasis.

IF 0.7 Q3 MEDICINE, GENERAL & INTERNAL

Annals of African Medicine Pub Date : 2025-08-04 DOI:10.4103/aam.aam_169_24

Neeraj Jain, Anshi Jain, Ramita Sharma

{"title":"Combination of Tapentadol Nasal Spray and Radiotherapy for Managing Moderate-to-Severe Pain from Lytic Bone Metastasis.","authors":"Neeraj Jain, Anshi Jain, Ramita Sharma","doi":"10.4103/aam.aam_169_24","DOIUrl":null,"url":null,"abstract":"Background: Tapentadol is known for its opioid-sparing effect, reducing adverse effects associated with opioids, particularly gastrointestinal issues. However, limitations in the oral formulation warrant exploration of alternatives like tapentadol nasal spray for enhanced efficacy and patient experience.Aims and objectives: This study aimed to assess the safety of tapentadol nasal spray (45mg/dose, administered four times daily) along with radiotherapy in patients with lytic bony metastasis moderate to severe pain.Materials and methods: 65 patients with lytic bony metastasis from solid tumours in 2023 were given local radiotherapy and tapentadol nasal spray (45mg/dose, administered four times daily).Results: Tapentadol nasal spray combined with radiotherapy demonstrated significant pain reduction. Sleep scores were significantly better with tapentadol nasal spray. The nasal route provided enhanced comfort, convenience, safety, and efficacy, offering rapid pain relief.Conclusion: Tapentadol nasal spray presents a favourable option for bone metastasis pain management along with radiotherapy, offering improved pain reduction, better sleep outcomes, and enhanced patient comfort. The nasal delivery method proves efficient and patient-friendly, marking a significant advancement in achieving early and sustained pain relief.","PeriodicalId":7938,"journal":{"name":"Annals of African Medicine","volume":" ","pages":""},"PeriodicalIF":0.7000,"publicationDate":"2025-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of African Medicine","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4103/aam.aam_169_24","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tapentadol is known for its opioid-sparing effect, reducing adverse effects associated with opioids, particularly gastrointestinal issues. However, limitations in the oral formulation warrant exploration of alternatives like tapentadol nasal spray for enhanced efficacy and patient experience.

Aims and objectives: This study aimed to assess the safety of tapentadol nasal spray (45mg/dose, administered four times daily) along with radiotherapy in patients with lytic bony metastasis moderate to severe pain.

Materials and methods: 65 patients with lytic bony metastasis from solid tumours in 2023 were given local radiotherapy and tapentadol nasal spray (45mg/dose, administered four times daily).

Results: Tapentadol nasal spray combined with radiotherapy demonstrated significant pain reduction. Sleep scores were significantly better with tapentadol nasal spray. The nasal route provided enhanced comfort, convenience, safety, and efficacy, offering rapid pain relief.

Conclusion: Tapentadol nasal spray presents a favourable option for bone metastasis pain management along with radiotherapy, offering improved pain reduction, better sleep outcomes, and enhanced patient comfort. The nasal delivery method proves efficient and patient-friendly, marking a significant advancement in achieving early and sustained pain relief.

查看原文本刊更多论文

他他多鼻喷雾剂联合放疗治疗溶解性骨转移所致中重度疼痛。

背景：他他多以其阿片类药物节约作用而闻名，可减少与阿片类药物相关的不良反应，特别是胃肠道问题。然而，口服制剂的局限性需要探索他他多鼻腔喷雾剂等替代品，以提高疗效和患者体验。目的和目的：本研究旨在评估他他多鼻喷雾剂（45mg/剂，每日4次）和放疗对中度至重度骨转移患者的安全性。材料与方法：对2023年65例实体瘤溶性骨转移患者行局部放疗加他他多鼻喷雾剂（45mg/剂，每日4次）治疗。结果：他他多鼻喷雾剂联合放疗可明显减轻疼痛。tapentadol鼻喷雾剂的睡眠评分明显更好。鼻路提供了更好的舒适性，便利性，安全性和有效性，提供快速缓解疼痛。结论：他他多鼻喷雾剂是治疗骨转移性疼痛和放疗的良好选择，可减轻疼痛，改善睡眠，提高患者舒适度。鼻给药方法被证明是高效且对患者友好的，标志着在实现早期和持续的疼痛缓解方面取得了重大进展。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of African Medicine MEDICINE, GENERAL & INTERNAL-

CiteScore

0.90

自引率

0.00%

发文量

期刊介绍： The Annals of African Medicine is published by the Usmanu Danfodiyo University Teaching Hospital, Sokoto, Nigeria and the Annals of African Medicine Society. The Journal is intended to serve as a medium for the publication of research findings in the broad field of Medicine in Africa and other developing countries, and elsewhere which have relevance to Africa. It will serve as a source of information on the state of the art of Medicine in Africa, for continuing education for doctors in Africa and other developing countries, and also for the publication of meetings and conferences. The journal will publish articles I any field of Medicine and other fields which have relevance or implications for Medicine.